ePrivacy and GPDR Cookie Consent by TermsFeed Generator
Request a Quote

Search

Industry Symposium + Breakfast | Using 3D Genomics to Understand Disease Progression and Prognosis in Pancreatic Cancer

Tuesday, June 11, 2024 | 8:30 – 9:15 
Rotterdam Room | Coffee and pastries will be provided

In this session, dive into the latest research in 3D genomics. Learn how this cutting-edge approach allows researchers to unravel novel disease mechanisms, identify therapeutic targets, and detect gene fusions crucial for cancer diagnostics.

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, largely due to its complex genomic architecture and resistance to conventional therapies. Explore how 3D genomics has been used to study the role of HMGB2, a protein linked to chromatin reorganization, in shaping the genomic landscape of PDAC. Learn how patient-derived organoids and primary tumor samples reveal distinct 3D chromatin conformations, offering new insights into disease mechanisms and potential therapeutic strategies.

What You Will Learn:

  1. Why is Hi-C compatible with FFPE tissues? Understand why an NGS approach like Hi-C is uniquely compatible with FFPE tissues to generate genome-wide data in primary tumor samples.
  2. How does 3D chromatin folding affect disease progression and divergent prognoses? Discover how mapping patient-specific chromatin landscapes reveals selection processes during organoid production. Learn about the connection between disease progression, prognosis, and the distinct 3D chromatin conformations observed in PDAC samples.
  3. What are the implications of pharmacologically targeting 3D genome folding for treatment? Explore how pharmacologically targeting HMGB2 affects tumor growth capacity and 3D genome folding, paving the way for novel therapeutic approaches in pancreatic cancer treatment.

Coffee and pastries will be provided.

Save Your Seat

Meet the Speakers:

Kristin Sikkink, PhD

Director of Research, Arima Genomics

Kristin is our newly appointed Director of Research and holds a PhD in Biology. She leads and manages Arima's clinical and discovery research programs.

Argyris Papantonis, PhD

Professor for Translational Epigenetics, University of Goettingen in Germany
Argyris studied biology at the University of Athens, where he also obtained his Ph.D. Following postdoctoral work with Peter R. Cook at the University of Oxford, he set up his lab at the Center for Molecular Medicine Cologne, Germany. Since 2018 he is a Professor for Translational Epigenetics at the Medical Faculty of the University of Goettingen, Germany.

Stop by our Poster Session:

Uncovering Gene Fusions with 3D Genomics: From Clinical Validation to Actionable Insights for Undiagnosable Solid Tumors

Abstract Number: EACR23-1524 Tuesday, June 13, 2023 | 17:00 – 18:00  During Poster Session: Biomarkers in Tissue and Blood (even Abstracts Numbers)

Kristin Sikkink, PhD

Director of Research, Arima Genomics